Tagged with LatAm

LatAm As selected by the Generics & Biosimilars Initiative (GABI), these are the top ten pharma companies ranked by turnover in Argentina, Brazil, Chile, Colombia, and Mexico for 2021. As the chart shows, the Argentinian and Brazilian Top Tens are dominated by domestic companies, while multinationals hold sway in Colombia and…

Mexico The Mexican Association of Pharmaceutical Research Industries (AMIIF) represents the innovative pharmaceutical industry in Mexico, advocating for innovation and promoting dialogue with local authorities. AMIIF’s Executive Director, Cristobal Thompson, discusses the country and the organization’s response to the COVID-19 pandemic and outlines Mexico’s healthcare challenges and how they have evolved…

Brazil Renata Mihich, a 25-year DHL veteran, recently took on a new role as Head of LatAm for Italian healthcare logistics specialist BOMI GROUP. At a moment of career transformation, BOMI GROUP is also on the verge of a big change with UPS Healthcare acquiring the company earlier this year. Mihich…

Pharma Legal Handbook Need to know about regulation, pricing and reimbursement in Colombian pharma? Read on! Prepared in association with Cavelier Abogados, a leading global law firm, this is an extract from The Pharma Legal Handbook: Colombia, available to purchase here for GBP 119.    1. What are the regulatory authorities with jurisdiction over…

Americas While regulatory agencies in several Latin American countries have made significant efforts to improve processes and accelerate approval times, a number of access hurdles still remain across the region. Here, the representatives of some of pharma’s most important companies in LatAm share their experiences of the evolution of market access…

Brazil Rolf Hoenger describes how Roche is driving access and awareness for innovative medicines in Latin America and weighs in on a number of important topics, from regulatory harmonisation in the region to digitalisation, clinical trials, Roche’s ongoing global transformation, and how inter-industry collaboration can foster true progress in healthcare.  …

Brazil After a successful international career, Andre Vivan da Silva recently returned to his native Brazil to become GSK’s country manager. He explains the importance of vaccination, in Brazil, and HIV in a country where GSK’s products treat at least half of its HIV patients. He also speaks about the company’s…

Americas Latin America (LatAm) Area Lead for Astellas Sandra Ramirez outlines the Japanese company’s presence in the region, its efforts to partner with local stakeholders to improve patient access, and the consolidation of its operations in the priority market of Mexico.   LatAm as a region offers many opportunities for innovation.…

Americas Two Big Pharma SVPs with responsibility for the entirety of Latin America weigh in on the management challenges inherent in LatAm and what they look for when appointing country managers in their region.   LatAm’s regional pharma market of USD 98 billion looks set to be the fastest growing in…

LatAm Novo Nordisk’s Latin America lead Allan Finkel outlines the “alarming” burden of diabetes and obesity in his region, the progress that has been made via national campaigns against diabetes, and why countries in LatAm need to recognise obesity as the disease it is considering its heavy impact on patients’ lives…

LatAm A roundup of some of the latest from Latin American pharma, including India’s interest in the South American market, Bayer’s USD 361 million investment in Mexico, the EU’s partnership to boost investment in vaccines and drug production in the region, Panama’s cannabis strategy, and Brazil’s manufacturing attractiveness.   Indian pharma…

LatAm GSK’s head of Emerging Markets, Luis Arosemena, comments on the strategic importance of this wide-ranging country grouping for the company, the structure of his organisation in Latin America, the importance of the country manager role, and explains how strong institutions make up for volatility in Latin America.   Five of…